- Home
- GLSI vs CSBR Comparison
GLSI vs CSBR Comparison
Compare GLSI & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- CSBR
- Stock Information
- Founded
- GLSI 2006
- CSBR 1985
- Country
- GLSI United States
- CSBR United States
- Employees
- GLSI N/A
- CSBR N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLSI Health Care
- CSBR Health Care
- Exchange
- GLSI Nasdaq
- CSBR Nasdaq
- Market Cap
- GLSI 133.4M
- CSBR 111.4M
- IPO Year
- GLSI 2020
- CSBR 1986
- Fundamental
- Price
- GLSI $9.27
- CSBR $7.52
- Analyst Decision
- GLSI Strong Buy
- CSBR Strong Buy
- Analyst Count
- GLSI 1
- CSBR 1
- Target Price
- GLSI $39.00
- CSBR $12.00
- AVG Volume (30 Days)
- GLSI 37.8K
- CSBR 39.2K
- Earning Date
- GLSI 08-13-2025
- CSBR 07-17-2025
- Dividend Yield
- GLSI N/A
- CSBR N/A
- EPS Growth
- GLSI N/A
- CSBR N/A
- EPS
- GLSI N/A
- CSBR 0.46
- Revenue
- GLSI N/A
- CSBR $58,591,000.00
- Revenue This Year
- GLSI N/A
- CSBR $15.11
- Revenue Next Year
- GLSI N/A
- CSBR $7.80
- P/E Ratio
- GLSI N/A
- CSBR $16.29
- Revenue Growth
- GLSI N/A
- CSBR 19.03
- 52 Week Low
- GLSI $8.06
- CSBR $3.60
- 52 Week High
- GLSI $18.15
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- GLSI 42.26
- CSBR 54.48
- Support Level
- GLSI $8.67
- CSBR $6.98
- Resistance Level
- GLSI $9.37
- CSBR $7.88
- Average True Range (ATR)
- GLSI 0.28
- CSBR 0.71
- MACD
- GLSI 0.00
- CSBR -0.01
- Stochastic Oscillator
- GLSI 28.74
- CSBR 57.14
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.